News

The trial is being performed under the direction of Drs. Filip Janku, M.D. and Gerald Falchook, M.D. as Co-Principal Investigators. Dr. Janku is Assistant Professor in the Department

Sectoral Asset Management and existing investors participated in the new funding round. In total, Effector has raised around $111m since its establishment in 2013. Effector’s lead compound is

In the phase III Ratify trial, patients who received PKC412 and chemotherapy experienced an increase in median overall survival compared to those receiving chemo alone (74.7 months versus

Under the trial, which is being undertaken in Stockholm, Sweden, two higher doses and volumes of BPZE1, 108 CFU and 109 CFU, will be studied as a follow-up

In the study, IW-1701 demonstrated the expected cardiovascular pharmacodynamic effects, proof of mechanism for sGC stimulation, a dose range that was well tolerated in healthy volunteers as a

The work, published online today in the journal Science, highlights the remarkable speed of Adimab’s recently launched single B cell isolation platform, and constitutes the largest panel of

The founders of include Pliant Therapeutics researchers from the University of California, San Francisco (UCSF) who have discovered crucial insights into the biology behind fibrosis and The researchers

During the trial, patients given 1.8 mg and 1.2 mg doses of the beloranib drug experienced 12.7% and 13.5% reduction in body weight, respectively. Patients given a placebo

The headline data dose-setting trial for the vaccine, GrassMATAMPL, is anticipated at the end of the first half of this year. The results of that will lead on